Xylazine: Clinical Implication for People Who Use Drugs & Harm Mitigation Strategies

Xylazine: Clinical Implication for People Who Use Drugs & Harm Mitigation Strategies

Ilana Hull, MD, MSc, board-certified family medicine and addiction medicine physician will discuss:

• the emergence of xylazine and other common adulterant in the United States illicit opioid supply potential clinical harms and public health implications of combined xylazine and opioid exposures
• harm reduction strategies to minimize risk of xylazine exposure
• impact of xylazine-related wounds on substance use treatment and other medical care
• best practices for clinical management of xylazine wounds

Learn more & register

For trainings that indicate Continuing Education Units (CEUs) are available, contact the organizer and/or the Vermont Office of Professional Regulation to verify that the credits will count toward the continuing education requirements of your licensure or certification.